Sudarshan Pharma (SUDARSHAN) | Stock Overview & Key Data
Sudarshan Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹32.95
High: ₹34.90
on August 22, 2025
52 Week Range
Low: ₹24.69
High: ₹452.70
on May 9, 2025
on October 3, 2024
All-Time High: ₹452.70 on September 30, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR7.7B
EPS
0.66
P/E Ratio (TTM)
48.45
Forward P/E
N/A
P/B Ratio
5.85
PEG Ratio
N/A
Div. Yield
N/A
ROE
12.14%
Beta
1.253
Debt to Equity
129.85
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
6.99%
Profit Margin
3.83%
Returns and Earnings
Return on Assets (TTM)
3.96%
Return on Equity (TTM)
12.14%
EBITDA
INR424.4M
Net Income (TTM)
INR211.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR22.90
Quarterly Revenue Growth (YoY)
46.40%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sudarshan Pharma SUDARSHAN | 7.70B Small-cap | 8.72% | 26.21% | 8.39% | 5.68% | -21.85% | -79.44% | -37.69% | -37.69% |
| Navin Fluorine NAVINFLUOR | 257.00B Large-cap | -0.24% | 0.74% | 16.41% | 28.62% | 53.36% | 52.80% | 19.25% | 135.76% |
| Deepak Nitrite DEEPAKNTR | 246.94B Large-cap | -0.29% | -6.36% | -12.83% | -7.35% | -27.74% | -36.01% | -7.93% | 141.40% |
| Styrenix Performance STYRENIX | 46.60B Small-cap | -4.19% | -17.48% | -13.12% | 4.56% | -14.71% | -6.16% | 181.39% | 394.77% |
| Gujarat Alkalies GUJALKALI | 41.50B Small-cap | 4.85% | -4.27% | -3.81% | 2.49% | -23.13% | -25.66% | -36.02% | 51.96% |
| Foseco India Limited FOSECOIND | 36.35B Small-cap | 34.78% | 31.77% | 39.03% | 85.03% | 55.71% | 33.02% | 266.07% | 392.84% |
Ownership & Short Interest
Insider Ownership
75.35%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
289K
Average 90-Day Volume
369K
Sudarshan Pharma Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Sudarshan Pharma would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SUDARSHAN's 52-week high and low?
- In the last 52 weeks, Sudarshan Pharma reached a high of ₹452.70 (on October 3, 2024) and a low of ₹24.69 (on May 9, 2025).
- What is the market cap and P/E ratio for SUDARSHAN?
- Curious about Sudarshan Pharma's size and valuation? Its market capitalization stands at 7.70B. When it comes to valuation, the P/E ratio (trailing twelve months) is 48.45, and the forward P/E (looking ahead) is N/A.
- Does SUDARSHAN pay dividends? If so, what's the yield?
- As for dividends, Sudarshan Pharma isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sudarshan Pharma's main competitors or similar companies to consider before investing?
When looking at Sudarshan Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Navin Fluorine
NAVINFLUOR257.00B Basic Materials Chemicals 52.80% 19.25% Deepak Nitrite
DEEPAKNTR246.94B Basic Materials Chemicals -36.01% -7.93% Styrenix Performance
STYRENIX46.60B Basic Materials Chemicals -6.16% 181.39% Gujarat Alkalies
GUJALKALI41.50B Basic Materials Chemicals -25.66% -36.02% Foseco India Limited
FOSECOIND36.35B Basic Materials Chemicals 33.02% 266.07% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sudarshan Pharma Industries Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Sudarshan Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 12.14%, the Debt to Equity ratio from the most recent quarter is 129.85, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for SUDARSHAN?
- Looking at Sudarshan Pharma's growth, its revenue over the trailing twelve months (TTM) was INR6B. Compared to the same quarter last year (YoY), quarterly revenue grew by 46.40%, and quarterly earnings saw a YoY growth of N/A.
- How much of SUDARSHAN stock is held by insiders and institutions?
- Wondering who owns Sudarshan Pharma stock? Company insiders (like executives and directors) hold about 75.35% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.